WO2014171172A1 - 血液処理用中空糸膜及び当該血液処理用中空糸膜の製造方法 - Google Patents
血液処理用中空糸膜及び当該血液処理用中空糸膜の製造方法 Download PDFInfo
- Publication number
- WO2014171172A1 WO2014171172A1 PCT/JP2014/053488 JP2014053488W WO2014171172A1 WO 2014171172 A1 WO2014171172 A1 WO 2014171172A1 JP 2014053488 W JP2014053488 W JP 2014053488W WO 2014171172 A1 WO2014171172 A1 WO 2014171172A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hollow fiber
- fiber membrane
- fat
- soluble substance
- blood
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 310
- 239000012510 hollow fiber Substances 0.000 title claims abstract description 251
- 210000004369 blood Anatomy 0.000 title claims abstract description 199
- 239000008280 blood Substances 0.000 title claims abstract description 199
- 238000011282 treatment Methods 0.000 title claims abstract description 74
- 238000004519 manufacturing process Methods 0.000 title abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 197
- 108010088751 Albumins Proteins 0.000 claims abstract description 107
- 102000009027 Albumins Human genes 0.000 claims abstract description 107
- 229920002492 poly(sulfone) Polymers 0.000 claims abstract description 40
- 229920005989 resin Polymers 0.000 claims abstract description 18
- 239000011347 resin Substances 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 18
- 150000002576 ketones Chemical class 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 230000035699 permeability Effects 0.000 abstract description 8
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 description 48
- 239000007788 liquid Substances 0.000 description 34
- 239000000243 solution Substances 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 30
- 239000002904 solvent Substances 0.000 description 26
- 238000000576 coating method Methods 0.000 description 22
- 239000011248 coating agent Substances 0.000 description 21
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 16
- 238000000502 dialysis Methods 0.000 description 16
- 239000011148 porous material Substances 0.000 description 14
- 239000012085 test solution Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 238000001035 drying Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 11
- 241000283690 Bos taurus Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000005194 fractionation Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000009987 spinning Methods 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000004695 Polyether sulfone Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 229920006393 polyether sulfone Polymers 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 239000002441 uremic toxin Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 238000000691 measurement method Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 229940087168 alpha tocopherol Drugs 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 229960000984 tocofersolan Drugs 0.000 description 4
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 4
- 239000002076 α-tocopherol Substances 0.000 description 4
- 235000004835 α-tocopherol Nutrition 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 238000004382 potting Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- -1 sucrose fatty acid esters Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 206010064553 Dialysis amyloidosis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 1
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009563 continuous hemofiltration Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000578 dry spinning Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000002166 wet spinning Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
- B01D67/0011—Casting solutions therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
- B01D67/0011—Casting solutions therefor
- B01D67/00113—Pretreatment of the casting solutions, e.g. thermal treatment or ageing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
- B01D69/087—Details relating to the spinning process
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/66—Polymers having sulfur in the main chain, with or without nitrogen, oxygen or carbon only
- B01D71/68—Polysulfones; Polyethersulfones
Definitions
- the present invention relates to a blood treatment hollow fiber membrane, in particular, a polysulfone blood treatment hollow fiber membrane and a method for producing the blood treatment hollow fiber membrane.
- blood purification therapy for the treatment of renal failure has been carried out by using polymers such as cellulose, cellulose acetate, polysulfone, polyethersulfone, polymethylmethacrylate, or polyacrylonitrile for the purpose of removing uremic toxins and waste products in the blood.
- Polymers such as cellulose, cellulose acetate, polysulfone, polyethersulfone, polymethylmethacrylate, or polyacrylonitrile for the purpose of removing uremic toxins and waste products in the blood.
- Hollow fiber membrane-type blood purifiers such as hemodialyzers, hemofilters or hemodialyzers equipped with the blood treatment hollow fiber membrane used as a separator are widely used. These hollow fiber membrane-type blood purifiers are excellent in reducing the amount of extracorporeal blood circulation, high efficiency of removing uremic substances in the blood, and high productivity during module production.
- Polysulfone-based hollow fiber membranes that can be compatible with each other are particularly excellent.
- Polysulfone-based hollow fiber membranes have a high affinity with fat-soluble vitamins that are effective in suppressing oxidative stress caused by extracorporeal circulation of blood, and lipid-soluble vitamins can be easily immobilized on the membrane surface. It is preferable also from a point (patent documents 1 and 2).
- ⁇ 1 microglobulin (molecular weight: 33,000) is controlled by controlling the ratio of both the blood contact side and the non-contact side of a hollow fiber membrane mainly composed of a polysulfone polymer and polyvinylpyrrolidone. ) And albumin have been reported to improve, but according to the experiments by the present inventors, the fractionation between ⁇ 2MG and albumin was not sufficient.
- albumin may be converted to uremic toxin by oxidative stress oxidizing albumin or adsorbing uremic toxin. According to this theory, it is believed that a certain amount of albumin should be actively removed to promote the metabolism of albumin, as is the case with living kidneys. Furthermore, a further highly permeable hollow fiber membrane is demanded together with the improvement in ⁇ 2MG removal amount that has been continuously demanded.
- Albumin is responsible for most of the osmotic pressure of the colloid, but the albumin leakage that causes a problem was not caused in the conventional hollow fiber membrane. According to the experiments by the present inventors, the amount of protein permeated by the hollow fiber membrane, which has been improved by extending the prior art to the initial level, is high at the beginning, rapidly decreases, and reaches a constant value after about 1 hour. For this reason, when a certain amount of albumin leakage is directed in a single treatment, the albumin concentration is drastically reduced immediately after the start of treatment, and the risk of imbalance syndrome may be increased more than before.
- the present invention is a hollow fiber membrane for blood processing that can be used in a blood purifier having high solute permeation performance that can realize a certain amount of albumin leakage in blood processing, and albumin leakage changes over time throughout the blood processing. It is an object of the present invention to provide a hollow fiber membrane for blood treatment that can be suppressed and a method for producing the same.
- the inventors of the present invention have a polysulfone-based hollow fiber membrane for blood treatment containing a polysulfone-based resin, a hydrophilic polymer, and a fat-soluble substance.
- a polysulfone-based resin containing a polysulfone-based resin, a hydrophilic polymer, and a fat-soluble substance.
- the content of the fat-soluble substance existing on the surface of the film is 40 to 40%.
- the polysulfone blood treatment hollow fiber membrane which is 95% by mass, and further, the clearance value of ⁇ 2MG converted to 1.5 m 2 of the blood purifier assembled using the membrane is 65 mL / min or more.
- the present invention is as follows. (1) In a polysulfone blood treatment hollow fiber membrane containing a polysulfone resin, a hydrophilic polymer and a fat-soluble substance, the amount of the fat-soluble substance present on the surface of the membrane is 10 to 300 mg per m 2 , and the membrane When the content of the fat-soluble substance existing in the whole is 100% by mass, the content of the fat-soluble substance existing on the surface of the membrane is 40 to 95% by mass, and the blood purifier assembled using the membrane A polysulfone blood treatment hollow fiber membrane having a clearance value of ⁇ 2MG converted to 1.5 m 2 of 65 mL / min or more.
- the present invention in addition to improving the fractionation property of ⁇ 2MG and albumin, it has high solute permeation performance that can realize a certain amount of albumin leakage in blood processing, and suppresses the amount of albumin leakage in the initial stage of blood processing.
- it is possible to provide a blood treatment hollow fiber membrane that continuously leaks albumin gently over the entire period of blood treatment, and a method for producing the blood treatment hollow fiber membrane.
- the present embodiment a mode for carrying out the present invention (hereinafter referred to as “the present embodiment”) will be described in detail.
- the present invention is not limited to the following description, and various modifications can be made within the scope of the gist thereof.
- the hollow fiber membrane for blood treatment of the present embodiment (hereinafter sometimes simply referred to as “hollow fiber membrane”) contains a polysulfone resin, a hydrophilic polymer, and a fat-soluble substance.
- the surface contains 10 to 300 mg of a fat-soluble substance per m 2 and the content of the fat-soluble substance present in the entire hollow fiber membrane is 100% by mass, the content of the fat-soluble substance present on the surface of the membrane is It is 40 to 95% by mass, and the clearance value of ⁇ 2MG in terms of 1.5 m 2 of a blood purifier assembled using a hollow fiber membrane is 65 mL / min or more.
- the hollow fiber membrane is a blood treatment hollow fiber membrane used in a blood purifier.
- the “blood purifier” is a device for purifying blood used for treatment of extracorporeal blood circulation, such as a hemodialyzer, a hemofiltration dialyzer, a hemofilter, and a continuous hemofiltration (dialysis) apparatus.
- the form such as the inner diameter, the film thickness, and the length can be arbitrarily adjusted.
- the inner diameter may be selected from a range of 100 to 300 ⁇ m
- the film thickness may be 10 to 100 ⁇ m
- the length may be selected from 10 to 40 cm.
- a so-called asymmetric membrane having a thin dense layer (active separation layer) and a porous layer (support layer) responsible for hollow fiber strength is preferable.
- the blood treatment hollow fiber membrane of the present embodiment may have the same structure as the conventionally known blood treatment hollow fiber membranes described in Patent Document 1 and Patent Document 2, for example.
- Hollow fiber membranes are not oriented to high permeation performance, for the purpose of alleviating the imbalance syndrome revealed by the present invention and the fractionation between ⁇ 2MG and albumin that is manifested in blood purifiers with high permeation performance Not in.
- the present invention is intended for hollow fiber membranes used in high-performance blood purifiers, and the clearance of ⁇ 2MG converted to 1.5 m 2 of the blood purifier assembled with the hollow fiber membranes of this embodiment is 65 mL / min or more. Yes, preferably 70 mL / min or more.
- the ⁇ 2MG clearance converted to 1.5 m 2 defined in the present invention is measured and calculated by the following method.
- the test solution used on the blood side is bovine plasma obtained by separating anticoagulated bovine whole blood into plasma.
- the anticoagulant may be a citric acid type or heparin.
- the plasma total protein is adjusted to 6.5 ⁇ 0.5 g / dL, and a commercially available ⁇ 2MG reagent is added to 0.01 to 4 mg / L.
- As the dialysate a commercially available dialysate having a pH of around 7.4 may be used, or an equivalent buffer may be prepared and used. Keep both the blood-side test solution and the dialysate-side test solution at 37 ⁇ 1 ° C.
- a blood purifier having a membrane area of 1.5 m 2 is set in the “single circuit” shown in FIG.
- the blood side inlet flow rate (QBi) of the blood purifier is 200 mL / min
- the blood outlet side flow rate (QBo) is 185 mL / min.
- the dialysate inlet flow rate (QDi) is adjusted to 500 mL / min.
- the blood is sampled from the blood supply liquid, the blood side test liquid outlet and the dialysate side test liquid outlet, and the respective ⁇ 2MG concentrations CBi, CBo and CDo are obtained. taking measurement.
- the ⁇ 2MG concentration may be measured using a commercially available device, or a measurement can be requested from a clinical laboratory.
- the clearance (CL) is calculated from Equation (1).
- the polysulfone-based resin of the present embodiment (hereinafter sometimes referred to as “PSf”) is a general term for polymer compounds having a sulfone bond, and is not particularly limited. Examples thereof include polysulfone polymers whose repeating units are represented by the following chemical formulas (1) to (5).
- n is a polymerization degree and may be an arbitrary value.
- PSf of the chemical formula (1) is commercially available from Solvay Advanced Polymers under the trade name “Udel”, and from BASF under the trade name “Ultrazone”. Depending on the type, there are a plurality of types, but there is no particular limitation.
- PSf of chemical formula (2) includes SUMIKAEXCEL PES (manufactured by Sumitomo Chemical Co., Ltd., product name), ultra zone (manufactured by BASF Corp., product name) and the like. These are widely available on the market, and are easily available and preferable. From the viewpoints of handling and availability, the reduced viscosity measured with a 1 (W / V)% DMF (dimethylformamide) solution is 0. It is preferably in the range of 30 to 0.60, more preferably in the range of 0.36 to 0.50.
- hydrophilic polymer examples include polyvinyl pyrrolidone (hereinafter sometimes referred to as “PVP”), polyethylene glycol, polyvinyl alcohol, polypropylene glycol, and the like. From the viewpoint of affinity, PVP is preferably used.
- PVP polyvinyl pyrrolidone
- PVP polyvinyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N
- the fat-soluble substance of the present embodiment generally means a substance that is hardly soluble in water and is soluble in alcohol and fats and oils, and natural products and synthetic products having low toxicity can be used. Specific examples include cholesterol, vegetable oils such as castor oil, lemon oil, and shea butter, animal oils such as fish oil, fatty acids such as sucrose fatty acid esters and polyglycerin fatty acid esters, isoprenoids, and hydrocarbons having a large carbon number.
- fat-soluble vitamins such as vitamin A, vitamin D, vitamin E, vitamin K, and ubiquinone are also preferably used. Among these, vitamin E is preferable from the viewpoint of not inducing a disorder even if it is excessively consumed.
- ⁇ -tocopherol As vitamin E, ⁇ -tocopherol, ⁇ -tocopherol acetate, ⁇ -tocopherol nicotinate, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol and the like, and mixtures thereof can be used.
- ⁇ -tocopherol is preferable because it is excellent in various physiological actions such as in vivo antioxidant action, biological membrane stabilizing action, and platelet aggregation inhibitory action, and has a high effect of suppressing the above-mentioned oxidative stress.
- the fat-soluble substance may be obtained by appropriately chemically modifying the compounds exemplified above for the purpose of adjusting the antioxidant power and affinity with the membrane substrate, improving the stability, or other purposes.
- the inventors of the present invention include a fat-soluble substance in a polysulfone blood treatment hollow fiber membrane constituting a blood purifier having a clearance value of ⁇ 2MG converted to 1.5 m 2 of 65 mL / min or more. Thus, it was found that albumin could be leaked out with improved fractionation.
- albumin has a hydrophobic surface in the molecule and adsorbs on the hydrophobic surface. For this reason, it is presumed that the membrane surface is also strongly adsorbed on the surface of the pores of the separation active layer that determines the molecular fraction of this embodiment in which the membrane surface is modified with a hydrophobic fat-soluble substance.
- albumin has a negative charge, and it is known that albumin leak can be suppressed by a negatively charged membrane.
- Albumin strongly adsorbed on the membrane surface exerts an electrostatic repulsion effect on albumin approaching later, but does not affect the permeability of uremic substances such as ⁇ 2MG having no charge.
- the fact that albumin is firmly adsorbed on the pore surface of the separation active layer means a reduction in the substantial inner diameter of the pore, and therefore the pore size distribution of the hollow fiber membrane of this embodiment is larger than that of the conventional hollow fiber membrane. It is set.
- the PSf hollow fiber membrane for blood purification forms a pore structure by phase separation induced by adding a non-solvent to a PSf solvent.
- the concentration of the solvent in the mixture of the PSf solvent and the non-solvent is 50 to 60%.
- the amount of the fat-soluble substance present on the surface of the membrane is 10 to 300 mg per 1 m 2 of membrane area, and the content of the fat-soluble substance in the entire hollow fiber membrane is 100% by mass. In this case, the content of the fat-soluble substance existing on the surface of the hollow fiber membrane is 40 to 95% by mass.
- the “content of the fat-soluble substance present on the surface of the hollow fiber membrane” refers to the content of the fat-soluble substance adhered, adsorbed or coated on the surface of the hollow fiber membrane, and the fat-soluble substance present on this surface
- the content of can be quantified by, for example, the content of a fat-soluble substance extracted by a solvent without breaking or dissolving the hollow fiber membrane.
- Fat-soluble substance that is present on the surface of the hollow fiber membrane is 10 mg / m 2 or more 300 mg / m 2 or less in the range in membrane area in terms of the hollow fiber membrane. It is preferably 50 to 250 mg / m 2 , more preferably 100 to 200 mg / m 2 .
- the membrane area of the hollow fiber membrane referred to in the present invention is the effective total surface area of the hollow fiber membrane involved in filtration and dialysis, specifically the inner surface area of the hollow fiber membrane, and the average of the hollow fiber membranes It is calculated from the product of the inner diameter (diameter), the circumference ratio, the number, and the effective length.
- the content of the fat-soluble substance present on the membrane surface is 10 mg / m 2 or more, uneven coating of the fat-soluble substance can be prevented, and the above-described control of albumin permeability can be obtained with good reproducibility. In addition, it can exhibit excellent antioxidant ability. On the other hand, if it exceeds 300 mg / m 2 , the active separation layer in the hollow fiber membrane may be completely clogged with the fat-soluble substance, so that the high permeability characteristic of the present invention cannot be achieved.
- the hollow fiber membrane blood purifier is disassembled, the hollow fiber membrane is collected, washed with water, and then dried. Subsequently, a surfactant that dissolves the fat-soluble substance, for example, 1% by mass of a polyethylene glycol-t-octylphenyl ether aqueous solution, is added to the precisely-dried hollow fiber membrane after drying, followed by stirring and extraction. The membrane area of the extracted hollow fiber membrane is calculated from the weight.
- a surfactant that dissolves the fat-soluble substance for example, 1% by mass of a polyethylene glycol-t-octylphenyl ether aqueous solution
- the quantitative operation is performed, for example, by the following liquid chromatography method, and the concentration of the fat-soluble substance in the extract is calculated using a calibration curve obtained from the peak area of the fat-soluble substance standard solution. Based on the obtained concentration and the membrane area of the extracted hollow fiber membrane, the extraction efficiency is 100%, and the amount of fat-soluble substance (mg / m 2 ) present on the surface of the hollow fiber membrane can be determined.
- the content of the fat-soluble substance present on the surface of the hollow fiber membrane is 40 to 95% of the content of the fat-soluble substance present in the entire hollow fiber membrane. Preferably it is 45 to 90%, more preferably 50 to 80%.
- the hollow fiber membrane blood purifier is disassembled, the hollow fiber membrane is collected, washed with water, and then dried. Subsequently, a PSf solvent such as N-methyl-2-pyrrolidone is added to the precisely dried and dried hollow fiber membrane and stirred and dissolved. The membrane area of the dissolved hollow fiber membrane is calculated from the weight. The quantitative operation is performed, for example, by liquid chromatography, and the concentration of the fat-soluble substance in the solution is calculated using a calibration curve obtained from the peak area of the fat-soluble substance standard solution. The mass (mg / m 2 ) of the fat-soluble substance contained in the hollow fiber membrane can be determined from the obtained concentration and the membrane area of the dissolved hollow fiber membrane.
- a PSf solvent such as N-methyl-2-pyrrolidone
- the ratio of the fat-soluble substance existing on the surface of the hollow fiber membrane can be calculated by Equation (5).
- the content of the fat-soluble substance existing on the surface of the hollow fiber membrane is 40% or less of the content of the fat-soluble substance in the entire hollow fiber membrane, it is difficult to improve the fractionation property and to smoothly leak out albumin. This is because the amount of the fat-soluble substance immobilized on the hollow fiber membrane surface decreases. In order to avoid this, increasing the fat-soluble substance content of the entire membrane is due to the fact that a large amount of the fat-soluble substance of the entire membrane moves to the membrane surface due to the heat history and time passage during storage of the blood purifier, resulting in improved permeation performance. Cannot be employed due to risk of change.
- the amount of albumin leakage in one treatment is 1.0 to 10 g / session, preferably 1.2 to 9.0 g / session, more preferably 1.5 to 8. 0 g / session is desirable. If the amount is less than 1.0 g / session, albumin that has become uremic toxin is removed, and the effect of promoting metabolism hardly appears. If the treatment more than 10 g / session is continued, there is a risk of developing hypoalbuminosis.
- the term “session” here means the treatment time for one blood treatment. For example, in the case of hemodialysis, 240 minutes (4 hours) is standard.
- the membrane area of the blood purifier used for the measurement is not particularly limited, but is preferably 1.5 m 2 which is the mainstream membrane area or the vicinity thereof.
- the leakage amount of albumin in one entire treatment when the blood purifier of this embodiment is used can be estimated by a simulated treatment experiment for 240 minutes (1 session) by the measurement method described below.
- bovine blood to which coagulation was suppressed by adding citric acid or sodium heparin, it was diluted with bovine plasma or physiological saline to prepare a hematocrit of 35 ⁇ 2% and a total protein concentration of 6.5 ⁇ 0.5 g / dL. .
- the commercially available dialysate was sent to the blood flow path of the blood purifier at 500 mL / min in one pass, and water removal was performed at 6 ml / min / m 2. Perform dialysis while performing the procedure.
- a commercially available dialysis machine (for example, DBG-03 manufactured by Nikkiso Co., Ltd.) is used for feeding the dialysate.
- the blood purifier is sufficiently replaced with physiological saline in advance.
- dialysate feeding and water removal are started, and sampling of the water removal solution is started. If it is difficult to sample only the dewatering solution, all of the dialysis waste solution may be collected. Accumulate dehydrated solution or dialysis waste solution for a predetermined period (eg, 0 to 5 minutes, then ⁇ 1 hour, then ⁇ 4 hours, or repeat 5 minutes integration for 4 hours) Conduct a test solution.
- the ratio of “value”) may be 50% or less, preferably 45% or less, and more preferably 40% or less. If this ratio exceeds 50%, the albumin concentration decreases immediately after the start of dialysis, and the risk of inducing an imbalance syndrome increases.
- the ratio of the albumin leakage amount 5-minute integrated value to the albumin leakage amount integrated value for 1 hour is determined by the above-described albumin leakage amount measurement method, What is necessary is just to measure the integrated value of 1 hour after a process start, respectively, and to calculate the ratio.
- the ratio of the 5-minute integrated value of albumin leakage to the albumin leakage over the entire period of blood treatment (sometimes referred to as “total integrated value of albumin leakage”) is 30% or less, preferably 25% or less, more preferably 20% or less. It is desirable to be. If this ratio exceeds 30%, the albumin concentration decreases immediately after the start of dialysis, and the risk of inducing an imbalance syndrome increases.
- the total treatment period (1 session) is 240 minutes (4 hours), and the total albumin leakage amount is the 4-hour albumin leakage integrated value.
- the ratio of the albumin leakage 5-minute integrated value to the albumin leakage total integrated value (or albumin leakage 4-hour integrated value) when the blood purifier of this embodiment is used is determined by the above-described albumin leakage measurement method. It is only necessary to measure the integrated value for 5 minutes after the start and the integrated value for 4 hours, which is the entire processing period, and calculate the ratio.
- the decrease in the performance of the hollow fiber membrane in the step of adding the fat-soluble substance is due to the fact that the fat-soluble substance and the base resin of the hollow fiber membrane have a low compatibility but the structure holding power of the base resin is reduced. This is presumably because the pore size distribution changes. If there is no compatibility between the hollow fiber membrane base resin and the fat-soluble substance, the fat-soluble substance only adheres as an oil layer to the surface of the membrane base and does not enter the membrane base PSf. It is presumed that the distribution does not change.
- the inventors of the present invention have added a ketone having 1 to 4 carbon atoms and / or an alcohol (hereinafter sometimes referred to as “component A”) to the fat-soluble substance, thereby improving the compatibility between the fat-soluble substance and the hydrophobic resin.
- component A a ketone having 1 to 4 carbon atoms and / or an alcohol
- the hollow fiber membrane of the present embodiment is a hollow fiber membrane composed of a hydrophobic resin, a hydrophilic resin, and a fat-soluble substance, and further preferably contains 2 to 3000 ⁇ g of component A per 1 g of the hollow fiber membrane. .
- the hollow fiber membrane of this embodiment can suppress the variation in the suppression of albumin leakage and can provide a more stable onset suppression effect of imbalance symptoms.
- Component A that is, a ketone and / or alcohol having 1 to 4 carbon atoms consists of a ketone having 1, 2, 3 or 4 carbon atoms and an alcohol having 1, 2, 3 or 4 carbon atoms. At least one compound selected from the group.
- component A include, but are not limited to, acetone, methyl ethyl ketone, methanol, ethanol, propyl alcohol, isopropyl alcohol, ethylene glycol, glycerin, and butyl alcohol. These single compounds may be used. Any combination of these compounds may be used. Of these, acetone, ethanol, and isopropyl alcohol are preferably used.
- an ether type or tetrahydrofuran other than Component A is used, for example, the hydrophobic resin swells or dissolves and the structure changes, so that the performance may be remarkably lowered.
- the amount of component A contained in the hollow fiber membrane is not particularly limited, but is preferably 2 to 3000 ⁇ g, more preferably 10 to 2000 ⁇ g, and further preferably 25 to 1 g per 1 g of the hollow fiber membrane. 1500 ⁇ g.
- the compatibility of a fat-soluble substance and hydrophobic resin can fully be reduced, the structure retention of a hollow fiber membrane can be ensured, and the fall of membrane performance can be prevented. If it is less than 2 ⁇ g, the performance change due to the presence / absence of the abundance is remarkable, and there is a possibility that the amount of albumin leakage varies.
- the content of component A contained in the hollow fiber membrane per 1 g of the hollow fiber membrane can be measured by the following method.
- the blood purifier is disassembled, the hollow fiber membrane is taken out, and water is removed using a commercially available centrifuge at 3500 rpm for 10 minutes or more.
- the mass of part or all of the hollow fiber membrane from which moisture has been removed is measured (referred to as “w1 (g)”).
- w2 (g) 100-fold amount of N-methyl-2-pyrrolidone
- w2 (g) 100-fold amount of N-methyl-2-pyrrolidone
- concentration x w / w%) of component A is measured, for example, by gas chromatography.
- the content of component A per 1 g of the hollow fiber membrane (“D (g / g hollow fiber membrane)”) is calculated by substituting the numerical values w1 and x into the following formulas (8) to (9).
- the hollow fiber membrane blood purifier is disassembled to take out the hollow fiber membrane bundle. After drying to a constant weight in a desiccator using calcium chloride or the like as a desiccant, this mass was precisely weighed ("w3 (g)"), and then N-methyl-2-pyrrolidone ("w4 (g)” Is added, stirred and dissolved, and then the concentration y (w / w%) of component A is calculated by the above method. Subsequently, the content of component A per 1 g of the hollow fiber membrane (“D (g / g hollow fiber membrane)”) is calculated by substituting w3 and y into the following formula (10).
- the hollow fiber membrane of this embodiment can be manufactured by utilizing a known dry / wet film forming technique.
- the method includes, for example, a spinning step of obtaining a membrane intermediate material containing a polysulfone-based resin and a hydrophilic polymer by a dry and wet spinning method, and a fixing step of immobilizing a fat-soluble material on the membrane intermediate material.
- a hollow forming agent that is a mixed solution of a solvent and a non-solvent of a polysulfone resin and in which the concentration of the solvent in the mixed solution is 50 to 60% may be used.
- PSf and hydrophilic polymer are dissolved in a common solvent to prepare a spinning dope.
- the common solvent is not particularly limited.
- DMAC dimethylacetamide
- a pore structure is formed by phase separation induced by adding a non-solvent to the PSf solvent.
- the non-solvent to be added is a mixture of PSf solvent and non-solvent, and the solvent concentration is 50 to 60%.
- an additive such as water may be added to the spinning dope for controlling the pore diameter of the target hollow fiber membrane.
- the PSf concentration in the spinning dope is not particularly limited as long as the membrane can be formed and the obtained membrane has a performance as a permeable membrane, preferably 5 to 35% by mass, more preferably 10 to 30% by mass.
- the PSf concentration should be low, and more preferably 10 to 25% by mass.
- the concentration of the hydrophilic polymer in the spinning dope with respect to PSf is preferably such that the mixing ratio of the hydrophilic polymer with respect to 100% by mass of PSf is 27% by mass or less, more preferably 18 to 27% by mass, and still more preferably 20 to 20%. Adjust to 27% by mass.
- the mixing ratio of the hydrophilic polymer with respect to PSf exceeds 27% by mass, the elution amount of the hydrophilic polymer tends to increase, and when it is less than 18% by mass, the hydrophilic polymer concentration on the surface of the hollow fiber membrane decreases, This is not preferable because it may cause a leucopenia symptom in which the leukocyte concentration in the patient's blood rapidly decreases.
- a tube-in-orifice type spinneret is used, and the spinning stock solution is discharged from the tube into the air simultaneously with the hollow inner solution for coagulating the spinning stock solution.
- the hollow inner liquid water or a coagulating liquid mainly composed of water can be used, and its composition and the like may be determined according to the permeation performance of the target hollow fiber membrane.
- a mixed solution of a solvent and water used for the spinning dope is preferably used.
- the concentration of the solvent is high.
- polysulfone represented by the above chemical formula (1) it is 50 to 70% by mass.
- An aqueous solution is required, more preferably 50 to 65% by mass.
- the hydrophilic polymer can be added to the hollow inner liquid so that the amount of the hydrophilic polymer is 0 to 2% by mass to adjust the amount of the hydrophilic polymer present on the inner surface of the hollow fiber membrane.
- the spinning dope discharged from the spinneret together with the hollow inner liquid travels through the idle running part and is introduced into the coagulation bath mainly composed of water installed at the bottom of the spinneret to complete the coagulation. Then, it winds up with a wet hollow fiber membrane winder to obtain a bundle of hollow fiber membranes, and then performs a drying treatment. Alternatively, after passing through the washing step, drying may be performed in a dryer to obtain a bundle of hollow fiber membranes.
- a hollow fiber membrane having excellent thrombogenicity and biocompatibility, and having a slight adhesion to the membrane surface such as protein and platelets can be obtained.
- Method for producing hollow fiber membrane blood purifier for example, a method of first manufacturing a hollow fiber membrane as described above and manufacturing a module using the hollow fiber membrane can be mentioned.
- the bundle of hollow fiber membranes described above is inserted into a cylindrical container having a predetermined fluid inlet / outlet, which is a liquid to be treated, and a potting agent such as polyurethane is injected into both ends of the bundle to form a potting layer. Then, both ends are sealed, and then the excess potting agent after curing is cut and removed to open the end face, and a header having a fluid inlet / outlet is attached.
- a potting agent such as polyurethane
- the fat-soluble substance is fixed as described later, and further sterilized as described later.
- the immobilization of the fat-soluble substance may be performed independently as described later, or may be performed simultaneously with the formation of the hollow fiber membrane. Furthermore, it is possible to fix at the stage of the hollow fiber membrane before modularization.
- a known method can be basically used for the step of immobilizing the fat-soluble substance on the hollow fiber membrane.
- the coating method is excellent in that it can realize production of a fat-soluble substance-immobilized film having various permeation performances using existing equipment and product lineup.
- the fat-soluble substance is added to the membrane forming stock solution during the production of the hollow fiber membrane so that the entire hollow fiber membrane contains the fat-soluble substance.
- a method in which a fat-soluble substance and a surfactant are added to the hollow inner liquid so that the inner surface of the hollow fiber membrane contains the fat-soluble substance for example, Patent No. 4038583 and International Publication No. WO 98/52683
- the fat-soluble substance solution consisting of the fat-soluble substance and the solvent of the fat-soluble substance flows into the hollow part of the hollow fiber membrane, so that the fat-soluble substance is applied to the inner surface of the hollow fiber membrane.
- the content of the fat-soluble substance is 10 mg to 300 mg per 1 m 2 of the hollow fiber membrane.
- Examples of the method for controlling the content within the range include the following methods.
- the addition concentration is adjusted to 0.4% by mass to 2% by mass, preferably 0.8% by mass to 1.5% by mass.
- the method of doing is mentioned as a preferable method.
- the added concentration is 0.4% by mass or more, the surface exposure amount of the fat-soluble substance can be sufficiently secured, and good antioxidant ability can be obtained.
- the content is 2% by mass or less, the strength of the hollow fiber membrane can be sufficiently ensured practically, and the risk of breakage of the hollow fiber membrane can be prevented.
- the concentration of the fat-soluble substance is adjusted in the range of 0.01 to 10% by mass, preferably 0.1 to 5% by mass, and the aqueous hollow inner liquid such as a surfactant is added. It is preferable to add an additive for solubilizing the fat-soluble substance in an amount 1/10 to 2 times that of the fat-soluble substance.
- a coating in which 0.1 to 2.0% by weight of the fat-soluble substance is dissolved in an aqueous alcohol solution such as 50 to 80% by mass of propanol.
- an aqueous alcohol solution such as 50 to 80% by mass of propanol.
- the coating temperature is desirably 40 ° C. or lower, preferably 30 ° C. or lower, more preferably 25 ° C. or lower. If the coating temperature is higher than 40 ° C., it is presumed that the ratio of the fat-soluble substance penetrating into the membrane base material is increased, and the above-described gentle albumin leakage may not be obtained.
- the ketone and / or alcohol having 1 to 4 carbon atoms can be contained in the hollow fiber membrane using the following method.
- a method of assembling a hollow fiber membrane blood purifier, passing a fat-soluble vitamin solution, and drying in a steam atmosphere of a ketone having 1 to 4 carbon atoms and / or alcohol can be mentioned.
- the coating solvent may be a ketone and / or alcohol having 1 to 4 carbon atoms, and the vapor atmosphere of the ketone and / or alcohol having 1 to 4 carbon atoms can be maintained by devising drying conditions. It is also possible to fix the ketone and / or alcohol having 1 to 4 carbon atoms by artificially containing the ketone and / or alcohol having 1 to 4 carbon atoms in the introduced drying gas.
- the sterilization method may be any method such as a radiation sterilization method or a steam sterilization method. Since a hollow fiber membrane containing a large amount of a fat-soluble substance has a risk of causing damage to the hollow fiber due to extreme heating, a radiation sterilization method is more preferable.
- a radiation sterilization method an electron beam, a gamma ray, an X-ray or the like can be used, and any of them may be used.
- the irradiation dose of radiation is usually 5 to 50 kGy in the case of ⁇ rays and electron beams, but is preferably irradiated in a dose range of 20 to 40 kGy.
- the hollow fiber membrane type blood purifier was disassembled, the hollow fiber membrane was collected, washed with water, and then vacuum dried at 40 ° C. until a constant weight was obtained.
- the dried hollow fiber membrane of 0.2 m 2 was weighed into a glass bottle, and 50 mL of N-methyl-2-pyrrolidone was added thereto, followed by stirring and dissolution.
- Quantification was performed by a liquid chromatograph method, and the amount of the fat-soluble substance in the extract was determined using a calibration curve obtained from the peak area of the fat-soluble substance standard solution.
- a high-performance liquid chromatograph manufactured by JASCO, UV-2075 plus intelligent UV / VIS Detector, PU-2080 plus intelligent HPLC pump, CO-2065 plus intelligent column, AS-2057 plus column 8).
- N-methyl-2-pyrrolidone as a mobile phase was passed at a flow rate of 0.5 mL / min.
- the concentration of the fat-soluble substance was determined from the area of the absorption peak at a wavelength of 295 nm with a UV detector, and the concentration of the fat-soluble substance was determined from the obtained concentration and the mass of the dissolved hollow fiber membrane.
- the content of fat-soluble substances that the (mg / m 2) was determined.
- the hollow fiber membrane type blood purifier was disassembled, the hollow fiber membrane was collected, washed with water, and then vacuum dried at 40 ° C. until a constant weight was obtained. Weigh 0.2m 2 of the hollow fiber membrane after drying into a glass bottle, add 80mL of 1% by weight Triton X-100 (Kishida Chemical, Chemical) aqueous solution, and apply ultrasonic vibration for 60 minutes at room temperature. Extraction of soluble material was performed.
- Quantification was performed by a liquid chromatograph method, and the amount of the fat-soluble substance in the extract was determined using a calibration curve obtained from the peak area of the fat-soluble substance standard solution.
- a high-performance liquid chromatograph (pump: JASCO PU-1580, detector: Shimadzu RID-6A, auto injector: Shimadzu SIL-6B, data processing: Tosoh GPC-8020, column oven: GL Sciences 556)
- a column (ODP-506E packed column for HPLC manufactured by Shodex Asahipak) was attached, and methanol for high performance liquid chromatography, which is a mobile phase, was passed at a flow rate of 1 mL / min at a column temperature of 40 ° C., and a wavelength of 295 nm with a UV detector.
- the fat-soluble substance concentration was determined from the area of the absorption peak at. Taking the extraction efficiency as 100%, the content (mg / m 2 ) of the fat-soluble substance present on the surface of the
- the content of the fat-soluble substance existing on the surface of the hollow fiber membrane is the content (mg / m 2 ) of the fat-soluble substance extracted from the surface of the hollow fiber membrane.
- the fat-soluble substance partially oxidized by the sterilization treatment was also included in the amount of the fat-soluble substance existing on the surface of the hollow fiber membrane. For this reason, in order to determine the amount of the partially oxidized fat-soluble substance, the fat-soluble substance used for preparing the calibration curve is previously irradiated with 50 kGy radiation in the air, the absorption peak of the partially oxidized fat-soluble substance is determined in advance, and the area calculation is performed. It was included in the peak group used for and added.
- the content (mg / m 2 ) of the fat-soluble substance present on the surface of the hollow fiber membrane is shown in Table 1 below.
- Table 1 the mass of the fat-soluble substance contained on the surface of the hollow fiber membrane was expressed as “VE content”.
- ⁇ Clearance value of ⁇ 2MG> Dissolve 30 g of trisodium citrate dihydrate, 23.2 g of glucose, 3.58 g of citric acid monohydrate and 2.51 g of sodium dihydrogen phosphate dihydrate in 1 L of water for injection to give an anticoagulant (CPD )created.
- Anticoagulated bovine blood was obtained by adding 614 mL of CPD to 5 L of fresh bovine blood. The obtained blood was centrifuged at 3500 rpm for 20 minutes to separate plasma. The obtained plasma was diluted with physiological saline to adjust the total protein concentration to 6.5 ⁇ 0.5 g / dL. Furthermore, 1 mg of ⁇ 2MG (Eiken Chemical) was added per liter to obtain a blood side test solution.
- a blood purifier having a membrane area of 1.5 m 2 is set in the “closed circulation circuit” shown in FIG. 2, the blood side inlet flow rate (QBi) of the blood purifier is set to 200 mL / min, and the blood outlet side flow rate (QBo) is set to 185 mL.
- the filtration flow rate (QF) was adjusted to 15 mL / min, respectively, and circulated for 1 hour. After 1 hour, the blood flow was reset to the “single circuit” shown in FIG. 1, the blood inlet flow rate (QBi) of the blood purifier was 200 mL / min, the blood outlet flow rate (QBo) was 185 mL / min, and the dialysate inlet flow rate (QDi).
- ⁇ Albumin leakage amount> The above anticoagulated bovine blood was diluted with bovine plasma or physiological saline to prepare a hematocrit of 35 ⁇ 2% and a total protein concentration of 6.5 ⁇ 0.5 g / dL. While circulating the blood through the blood flow path of the blood purifier at 200 mL / min, a commercially available dialysate (manufactured by Fuso Yakuhin Kogyo Co., Ltd., kindly dialysate AF2) is sent to the blood flow path of the blood purifier at 500 mL / min in one pass. Then, dialysis was performed while removing water at 6 ml / min / m 2 .
- albumin leakage amount is measured three times under one condition: (1) 5-minute integration point, (2) 1-hour integration point, and (3) 4-hour integration point.
- DBG-03 manufactured by Nikkiso Co., Ltd. was used for feeding the dialysate. In order to prevent hemolysis, the blood purifier is sufficiently replaced with physiological saline in advance.
- test solution (3) was obtained. Each test solution was mixed well, and the albumin concentration (unit: g / mL) in the test solution was determined using an automatic analyzer Biolis24i (Tokyo) using Iatro U-ALB (TIA) reagent (Mitsubishi Chemical Rulece Co., Ltd.).
- the ratio of the values is expressed by the following formula (11), formula (12), formula (13), formula (14), and formula from the concentrations of the test solutions (1) to (3) and the amount of the dehydrating solution (unit: mL). Calculated according to (15).
- component A The content per 1 g of hollow fiber membranes of ketones and / or alcohols having 1 to 4 carbon atoms (hereinafter referred to as “component A”) in the hollow fiber membrane blood purifier was measured by the following method.
- the blood purifier was disassembled, the hollow fiber membrane was taken out, and water was removed by centrifugation at 3500 rpm for 10 minutes using a commercially available centrifuge. Of the hollow fiber membrane from which moisture was removed, 0.25 g was weighed (this mass was referred to as “w1 (g)”). After 25 g of N-methyl-2-pyrrolidone was added and dissolved, components A, diethyl ether and tetrahydrofuran were quantified by gas chromatography (GC). Using the calibration curve obtained from the peak area of the corresponding component A, the concentration x (%) of component A, diethyl ether and tetrahydrofuran in the recovered liquid was determined.
- GC gas chromatography
- the hollow fiber membrane blood purifier was disassembled, and the hollow fiber membrane bundle was taken out. After drying to a constant weight in a desiccator as a calcium chloride desiccant, this mass was precisely weighed (“w3 (g)”) and then N-methyl-2-pyrrolidone (referred to as “w4 (g)”) Was added, stirred and dissolved, and then the concentration y (w / w%) of component A was calculated by the above method. Subsequently, the content of component A per 1 g of the hollow fiber membrane was calculated by substituting w3 and y into the following formula (16).
- Example 1 17.5% by weight of polysulfone (P-1700 manufactured by Solvay) and 3.5% by weight of polyvinylpyrrolidone (K90 manufactured by BASF) were dissolved in 79.0% by weight of N, N-dimethylacetamide to obtain a uniform solution. .
- the mixing ratio of polyvinylpyrrolidone to polysulfone in the membrane forming stock solution was 20.0% by weight.
- This film-forming stock solution was kept at 60 ° C. and discharged from a double annular nozzle together with an internal solution composed of a mixed solution of 58.1% by weight of N, N-dimethylacetamide and 41.9% by weight of water.
- the dry membrane is filled into a cylindrical container having two nozzles for introducing and discharging liquid, and both ends are embedded with urethane resin, and then the cured urethane portion is cut to open the hollow fiber membrane. Processed to the end.
- a header cap having a blood introduction (lead-out) nozzle was loaded at both ends, and assembled into a blood purification device having a hollow fiber membrane area of 1.5 m 2 .
- a coating solution in which 0.45% by weight of ⁇ -tocopherol (special grade manufactured by Wako Pure Chemical Industries, Ltd.) as a fat-soluble substance was dissolved in an aqueous solution of 57% by weight of isopropanol was dissolved in a blood purification apparatus at room temperature of 25 ° C.
- a lipid-soluble substance was brought into contact with the blood introduction nozzle through the lumen of the hollow fiber membrane for 52 seconds.
- the solvent is removed by drying by blowing dry air in an isopropanol atmosphere at 24 ° C. blown with isopropanol vapor for 30 minutes, thereby fixing the fat-soluble substance by coating. Turned into.
- an aqueous solution containing 0.06% sodium pyrosulfite, which is a sterilizing protective agent, and 0.03% sodium carbonate for pH adjustment is added to the blood side flow path and the filtrate side flow path of the blood purification apparatus.
- the blood purification apparatus of the present invention was obtained by filling and sterilizing ⁇ rays with 25 kGy with each nozzle sealed.
- the fat-soluble substance present on the inner surface with respect to the fat-soluble substance present in the entire hollow fiber membrane was 70 mL / min, and the content of component A in 1 g of the hollow fiber membrane was 2000 ⁇ g.
- Example 2 Except that N, N-dimethylacetamide in the internal liquid was 57.1% by weight, the concentration of the fat-soluble substance in the coating solution was 0.15% by mass, and ethanol vapor was blown into dry air, the same method as in Example 1 was used. A blood purifier was obtained. As a result of measuring the content of the fat-soluble substance in the hollow fiber membrane in the blood purifier obtained, 20.0 mg / m 2 , the fat-soluble substance present on the inner surface with respect to the fat-soluble substance present in the entire hollow fiber membrane The percentage of ⁇ 2MG was 70 mL / min, and the content of component A (in this case, ethanol) in 1 g of the hollow fiber membrane was 2000 ⁇ g.
- component A in this case, ethanol
- Example 3 Except that N, N-dimethylacetamide in the internal liquid was 59.5% by weight, the concentration of the fat-soluble substance in the coating solution was 0.90% by mass, and acetone vapor was blown into dry air, the same method as in Example 1 was used. A blood purifier was obtained. As a result of measuring the content of the fat-soluble substance in the hollow fiber membrane in the blood purifier obtained, 200.0 mg / m 2 , the fat-soluble substance present on the inner surface with respect to the fat-soluble substance present in the entire hollow fiber membrane The content of component A (here, acetone) in 1 g of the hollow fiber membrane was 2000 ⁇ g.
- component A here, acetone
- Example 4 Example, except that 55.0% by weight of N, N-dimethylacetamide in the internal liquid was used, and polyethersulfone (4800P manufactured by Sumitomo Chemical Co., Ltd.) represented by chemical formula (2) was used instead of polysulfone represented by chemical formula (1).
- a blood purifier was obtained in the same manner as in 1.
- the fat-soluble substance present on the inner surface with respect to the fat-soluble substance present in the entire hollow fiber membrane was 60 ⁇ g.
- Example 5 A blood purifier was obtained in the same manner as in Example 1 except that the internal liquid N, N-dimethylacetamide was changed to 55.5% by weight.
- the ratio of the fat-soluble substance present on the inner surface with respect to the fat-soluble substance present in the entire hollow fiber membrane was 60.0 mg / m 2 .
- the clearance of ⁇ 2MG was 65 mL / min
- the content of component A (in this case, isopropanol) in 1 g of the hollow fiber membrane was 2000 ⁇ g.
- Example 6 A blood purifier was obtained in the same manner as in Example 1 except that the fat-soluble substance coating solution was passed through the lumen of the hollow fiber membrane at 40 ° C. and dried. As a result of measuring the content of the fat-soluble substance in the hollow fiber membrane in the obtained blood purifier, 60.0 mg / m 2 , the fat-soluble substance present on the inner surface with respect to the fat-soluble substance present in the entire hollow fiber membrane The content of component A (here, isopropanol) in 1 g of the hollow fiber membrane was 10 ⁇ g.
- component A here, isopropanol
- Example 7 A blood purifier was obtained in the same manner as in Example 1, except that the fat-soluble substance coating solution was passed through the lumen of the hollow fiber membrane at 20 ° C. and dried. As a result of measuring the content of the fat-soluble substance in the hollow fiber membrane in the obtained blood purifier, 60.0 mg / m 2 , the fat-soluble substance present on the inner surface with respect to the fat-soluble substance present in the entire hollow fiber membrane The percentage of ⁇ 2MG was 70 mL / min, and the content of component A (here, isopropanol) in 1 g of the hollow fiber membrane was 3000 ⁇ g.
- component A here, isopropanol
- Example 1 A blood purifier was obtained in the same manner as in Example 1 except that 55.5% by weight of N, N-dimethylacetamide in the internal liquid, a fat-soluble substance coating step and a component A immobilization step were not included.
- the ratio of the fat-soluble substance present on the inner surface to the fat-soluble substance present in the entire hollow fiber membrane is 0 mg / m 2 .
- the clearance of mass%, ⁇ 2MG was 70 mL / min, and the content of component A in 1 g of the hollow fiber membrane was 0 ⁇ g.
- Example 2 A blood purifier was obtained in the same manner as in Example 1 except that the internal liquid N, N-dimethylacetamide was changed to 48.0% by weight.
- the content of the fat-soluble substance in the hollow fiber membrane in the obtained blood purifier 60 mg / m 2
- the ratio of the fat-soluble substance present on the inner surface to the fat-soluble substance present in the entire hollow fiber membrane was 70% by mass
- the clearance of ⁇ 2MG was 45 mL / min
- the content of component A (here, isopropanol) in 1 g of the hollow fiber membrane was 2000 ⁇ g.
- a blood purifier was obtained by the same method as in Comparative Example 2 except that the fat-soluble substance coating step was not performed.
- the content of the fat-soluble substance in the hollow fiber membrane in the obtained blood purifier 0 mg / m 2
- the ratio of the fat-soluble substance present on the inner surface to the fat-soluble substance present in the entire hollow fiber membrane was 0 mass%
- the clearance of ⁇ 2MG was 45 mL / min
- the content of component A in 1 g of the hollow fiber membrane was 0 ⁇ g.
- the ratio of the fat-soluble substance present on the inner surface to the fat-soluble substance present in the entire hollow fiber membrane is 0 mg / m 2 .
- the clearance of 0% by mass, ⁇ 2MG clearance was 60 mL / min, and the content of component A (here, isopropanol) in 1 g of the hollow fiber membrane was 2000 ⁇ g.
- Example 5 A blood purifier was obtained in the same manner as in Example 1 except that the fat-soluble substance coating solution was passed through the lumen of the hollow fiber membrane at 55 ° C. and dried. As a result of measuring the content of the fat-soluble substance in the hollow fiber membrane in the obtained blood purifier, 60.0 mg / m 2 , the fat-soluble substance present on the inner surface with respect to the fat-soluble substance present in the entire hollow fiber membrane The content of component A (here, isopropanol) in 1 g of the hollow fiber membrane was 2000 ⁇ g.
- component A here, isopropanol
- a blood purifier was obtained in the same manner as in Example 1 except that the vapor of component A was not blown into the dry air and the drying temperature was 80 ° C. .
- the content of the fat-soluble substance in the hollow fiber membrane in the obtained blood purifier it was 60.0 mg / m 2 , the fat-soluble substance present on the inner surface with respect to the fat-soluble substance present in the entire hollow fiber membrane.
- the ratio was 70% by mass, the clearance of ⁇ 2MG was 70 mL / min, and the content of component A (here, isopropanol) in 1 g of the hollow fiber membrane was 1 ⁇ g.
- a blood purifier was obtained by the same method as in Example 1 except that the dry air was changed to a diethyl ether atmosphere. An attempt was made to measure various physical properties of the hollow fiber membrane of the blood purifier obtained, but the amount of liquid permeation through the membrane was too small to measure.
- Example 8 After removing the remaining solution of the coating solution present in the lumen, a blood purifier was obtained in the same manner as in Example 1 except that the dry air was changed to a tetrahydrofuran atmosphere. An attempt was made to measure various physical properties of the hollow fiber membrane of the blood purifier obtained, but the amount of liquid permeation through the membrane was too small to measure.
- Example 1 By comparing Example 1 with Comparative Example 1, the inclusion of the fat-soluble substance in the hollow fiber membrane suppresses albumin leakage over the entire period, and further suppresses the rate of albumin leakage until 5 minutes after the start of blood treatment It was found to have an effect on
- Example 1 the mass ratio of the fat-soluble substance present on the surface of the hollow fiber membrane to the fat-soluble substance present in the entire hollow fiber membrane reduces the total leakage amount of albumin. , And was found to affect the suppression of the leak rate for 5 minutes.
- the hollow fiber membrane for blood treatment of the present invention in addition to improving the fractionation property of ⁇ 2MG and albumin, it has high solute permeation performance capable of realizing a certain amount of albumin leakage in blood treatment, It is possible to provide a blood purifier that can simultaneously suppress dialysis complications such as dialysis amyloidosis and dialysis imbalance syndrome by suppressing the amount of albumin leaked, in other words, by continuing to leak albumin gently throughout the entire blood treatment period. became.
- the hollow fiber membrane for blood treatment of the present invention has industrial applicability as a blood purifier such as a hemodialyzer, a hemofilter, or a hemodialysis filter.
Abstract
Description
(1)ポリスルホン系樹脂、親水性高分子及び脂溶性物質を含む、ポリスルホン系血液処理用中空糸膜において、膜の表面に存在する脂溶性物質の量が1m2あたり10~300mgであり、膜の全体に存在する脂溶性物質の含有量を100質量%とした場合、膜の表面に存在する脂溶性物質の含有量が40~95質量%であり、膜を用いて組み立てられた血液浄化器の1.5m2換算したβ2MGのクリアランス値が65mL/min以上である、ポリスルホン系血液処理用中空糸膜。
(2)血液処理開始から1時間後までのアルブミン漏出の合計量を100質量%とした場合、血液処理開始から5分間後までのアルブミン漏出量が50%以下である、(1)のポリスルホン系血液処理用中空糸膜。
(3)血液処理の全期間にわたるアルブミン漏出の合計量が1.0g/session以上である、(1)又は(2)のポリスルホン系血液処理用中空糸膜。
(4)1.5m2換算したβ2MGのクリアランスが70mL/min以上である、(1)~(3)のいずれかのポリスルホン系血液処理用中空糸膜。
(5)脂溶性物質が脂溶性ビタミンである、(1)~(4)のいずれかのポリスルホン系血液処理用中空糸膜。
(6)炭素数が1~4のケトン及び/又はアルコールを中空糸膜1gあたり2~3000μg含むことを特徴とする、(1)~(5)のいずれかのポリスルホン系血液処理用中空糸膜。
本実施形態の血液処理用中空糸膜(以下、単に「中空糸膜」と記載する場合がある。)は、ポリスルホン系樹脂、親水性高分子及び脂溶性物質を含み、中空糸膜は膜の表面に1m2あたり脂溶性物質を10~300mg含有し、中空糸膜の全体に存在する脂溶性物質の含有量を100質量%とした場合、膜の表面に存在する脂溶性物質の含有量が40~95質量%であり、中空糸膜を用いて組み立てられた血液浄化器の1.5m2換算したβ2MGのクリアランス値が65mL/min以上であるものである。
佐藤威ら、日本透析医学会誌(1996年)Vol.29(8)、P.1231~1245の規定する測定方法に準じてβ2MGのクリアランスを測定する。以下、具体例を紹介するが、その趣旨の範囲内で変形して実施しても構わない。
ただしQBi=200mL/min、QDi=500mL/min、
A=供試モジュールの膜面積(m2)、
CL=クリアランス測定値(mL/min)
本実施形態のポリスルホン系樹脂(以下、場合によって「PSf」という。)とは、スルホン結合を有する高分子化合物の総称であり、特に限定されるものではない。例えば、繰り返し単位が、下記化学式(1)~(5)で示されるポリスルホン系高分子が挙げられる。なお、nは重合度であり任意の値でよい。
本実施形態の親水性高分子としては、例えば、ポリビニルピロリドン(以下「PVP」と称することがある)、ポリエチレングリコール、ポリビニルアルコール、ポリプロピレングリコール等が挙げられるが、紡糸の安定性や、PSfとの親和性の観点から、PVPが好ましく用いられる。
本実施形態の脂溶性物質とは、一般に水に溶けにくく、アルコールや油脂に溶ける物質を言い、毒性が低い天然物や合成物を用いることができる。具体的にはコレステロール、ヒマシ油・レモン油・シアバターなどの植物油、魚油などの動物油、ショ糖脂肪酸エステル・ポリグリセリン脂肪酸エステルなどの脂肪酸、イソプレノイド、炭素数の大きな炭化水素などが挙げられる。また、脂溶性のビタミンである、ビタミンA、ビタミンD、ビタミンE、ビタミンK、及びユビキノンなども好ましく用いられる。これらの中では、過剰摂取をしても障害を誘発しないという観点から、ビタミンEが好適である。
本実施形態の中空糸膜は、膜の表面に存在する脂溶性物質の量が膜面積1m2あたり10~300mgであり、さらに、中空糸膜の全体における脂溶性物質の含有量を100質量%とした場合、中空糸膜の表面に存在する脂溶性物質の含有量が40~95質量%である。なお、「中空糸膜の表面に存在する脂溶性物質の含有量」とは、中空糸膜の表面に付着、吸着又は被覆した脂溶性物質の含有量をいい、この表面に存在する脂溶性物質の含有量は、例えば、中空糸膜を破壊又は溶解せずに溶媒によって抽出される脂溶性物質の含有量によって定量することができる。
高速液体クロマトグラフ装置(ポンプ:日本分光PU-1580、検出器:島津RID-6A、オートインジェクター:島津SIL-6B、データ処理:東ソーGPC-8020、カラムオーブン:GL Sciences556)に、カラム(Shodex Asahipak社製ODP-506E packed column for HPLC)を取り付け、カラム温度40℃において、移動相である高速液体クロマトグラフィー用メタノールを、例えば流量1mL/minで通液し、UV検出器で波長295nmにおける吸収ピークの面積から脂溶性物質濃度を求める。
本実施形態の中空糸膜における中空糸膜の表面に存在する脂溶性物質の含有量は中空糸膜の全体に存在する脂溶性物質の含有量の40~95%である。好ましくは45~90%、より好ましくは50~80%である。
血液処理として血液透析を例にすると1回の治療全体でアルブミンの漏出量は1.0~10g/session、好ましくは1.2~9.0g/session、さらに好ましくは、1.5~8.0g/sessionであることが望ましい。1.0g/sessionよりも少ないと、尿毒素となったアルブミンを除去し、新陳代謝を促す効果が現れがたく、10g/sessionよりも多い治療を継続すると低アルブミン症を発症するリスクが生じる。なおここでいうsessionとは1回の血液処理の治療時間を意味しており、例えば血液透析の場合は240分間(4時間)が標準的である。本発明者らの行った実験によれば膜面積あたりの濾過流量を一定にすれば血液浄化器の膜面積の変更はアルブミン漏出量測定値に大きな差を与えない。このため測定に使用する血液浄化器の膜面積は特に限定されないが、主流膜面積である1.5m2又はその近辺であることが好ましい。本実施形態の血液浄化器を用いた場合の1回の治療全体でのアルブミンの漏出量は以下に説明する測定方法によって、240分間(1 session)の模擬治療実験により推定することができる。
アルブミン漏出量の測定方法について、血液処理治療のひとつである透析治療を例にして以下に説明する。
血液処理開始から1時間後までのアルブミン漏出量(場合によって「アルブミン漏出量1時間積算値」という)に対する、血液処理開始から5分間後までのアルブミン漏出量(場合によって「アルブミン漏出量5分間積算値」という)の比率は50%以下であればよく、好ましくは45%以下、さらに好ましくは40%以下である。この比率が50%を超えると透析開始直後のアルブミン濃度低下が激しく、不均衡症候群を誘発するリスクが高まる。本実施形態の血液浄化器を用いた場合のアルブミン漏出量1時間積算値に対するアルブミン漏出量5分間積算値の比率は、上記アルブミン漏出量測定方法によって、血液処理開始後5分間の積算値と血液処理開始後1時間の積算値をそれぞれ測定してその比を算出すればよい。
血液処理の全期間にわたるアルブミン漏出(場合によって「アルブミン漏出量全積算値」という)に対する、アルブミン漏出量5分間積算値の比率は30%以下、好ましくは25%以下、さらに好ましくは20%以下であることが望ましい。この比率が30%を超えると透析開始直後のアルブミン濃度低下が激しく、不均衡症候群を誘発するリスクが高まる。なお、本実施形態においては、治療全期間(1 session)を240分間(4時間)とし、アルブミン漏出量全積算値をアルブミン漏出量4時間積算値とする。本実施形態の血液浄化器を用いた場合のアルブミン漏出量全積算値(又はアルブミン漏出量4時間積算値)に対するアルブミン漏出量5分間積算値の比率は、上記アルブミン漏出量測定方法によって、血液処理開始後5分間の積算値と全処理期間である4時間の積算値をそれぞれ測定してその比を算出すればよい。
従来においては、脂溶性物質を添加する工程において、中空糸膜の性能低下が生じる場合があった。上述したように、本発明者らは本願のなだらかにアルブミンを漏出させる効果は膜の分離活性層に少数存在する粗大孔に由来すると推定している。このため脂溶性物質を添加する工程において、膜の孔径分布の変化が生じると、所望のレベルのアルブミン漏出が得られず、過大あるいは過少となるリスクがあった。脂溶性物質を添加する工程における中空糸膜の性能低下は、脂溶性物質と、中空糸膜の基材樹脂とが、低いながらも相溶性を有し、基材樹脂の構造保持力が低下し、孔径分布が変化するためであると推測される。仮に中空糸膜の基材樹脂と、脂溶性物質とに相溶性が全く無ければ、脂溶性物質は、膜基材の表面に油層として付着するのみで膜基材PSfに入り込むことは無く、孔径分布の変化も生じないと推測される。
血液浄化器を解体し、中空糸膜を取り出し、市販の遠心分離機を用いて3500rpmで10分間、あるいはそれ以上の条件にて水分を除去する。水分を除去した中空糸膜の一部または全部の質量を測定する(「w1(g)」とする)。測定後、例えば100倍量のN-メチル-2-ピロリドン(「w2(g)」とする)を加えて溶解し、例えばガスクロマトグラフにより成分Aの濃度x(w/w%)を測定する。中空糸膜1gあたりの成分Aの含有量(「D(g/g中空糸膜)」)を、以下の数式(8)~(9)に数値w1、xを代入して算出する。
中空糸膜型血液浄化器の解体を行って、中空糸膜束を取り出す。塩化カルシウムなどを乾燥剤としたデシケーター中で恒量となるまで乾燥を行い、この質量を精秤した(「w3(g)」)後、N-メチル-2-ピロリドン(「w4(g)」とする)を加え、攪拌し、溶解した後、上記方法で成分Aの濃度y(w/w%)を算出する。続いて、w3とyを以下の数式(10)に代入して中空糸膜1gあたりの成分Aの含有量(「D(g/g中空糸膜)」)を算出する。
本実施形態の中空糸膜は、公知の乾湿式製膜技術を利用することにより製造できる。該方法は、例えばポリスルホン系樹脂及び親水性高分子を含む膜中間物質を乾湿式紡糸法で得る紡糸工程と、膜中間物質に脂溶性物質を固定化する固定工程とを有し、また、紡糸工程において、ポリスルホン系樹脂の溶媒及び非溶媒の混合液であって、混合液における溶媒の濃度が50~60%である中空形成剤を用いてもよい。
本実施形態の中空糸膜型の血液浄化器の好ましい製造方法としては、例えば、先ず、上述したように中空糸膜を製造し、当該中空糸膜を用いてモジュールを製造する方法が挙げられる。
中空糸膜へ脂溶性物質を固定化する工程は、基本的に公知の方法を用いることができる。中でもコート法は、既存の設備や製品ラインナップを利用して様々な透過性能を有する脂溶性物質固定化膜生産を実現できるという点で優れている。
加熱温度を100℃以上とすることにより、脂溶性物質の偏在効果を発揮でき、一方で180℃以下とすることにより、中空糸膜の軟化や透過性能の変化を防止することができる。
炭素数1~4のケトン及び/又はアルコールは、以下の方法を用いて中空糸膜に含有させることができる。例えば、中空糸膜型の血液浄化器を組み立て、脂溶性ビタミン溶液を通液させた後、炭素数1~4のケトン及び/又はアルコールの蒸気雰囲気下において乾燥させる方法が挙げられる。具体的にはコート溶媒を炭素数1~4のケトン及び/又はアルコールとし、乾燥条件を工夫することにより炭素数1~4のケトン及び/又はアルコールの蒸気雰囲気を保持することもできる。導入する乾燥用気体に炭素数1~4のケトン及び/又はアルコールを人為的に含有させることにより蒸気雰囲気を保持し、炭素数1~4のケトン及び/又はアルコールの固定を行うこともできる。
上述した中空糸膜型の血液浄化器に対して、滅菌処理を施すことが好ましい。滅菌方法には放射線滅菌法、蒸気滅菌法等、いずれの方法であってもよい。脂溶性物質を多量に含む中空糸膜は、極度な加熱により中空糸破損を起こすリスクが生じるため、放射線滅菌法がより好ましい。放射線滅菌法には、電子線、ガンマ線、エックス線等を用いることができるが、いずれを用いてもよい。放射線の照射線量は、γ線や電子線の場合は通常5~50kGyであるが、20~40kGyの線量範囲で照射することが好ましい。
中空糸膜型の血液浄化器を分解して中空糸膜を採取し、水洗した後、恒量となるまで40℃で真空乾燥した。乾燥後の中空糸膜0.2m2をガラス瓶に秤取し、N-メチル-2-ピロリドンを50mL加え、攪拌・溶解を行った。
中空糸膜の表面に存在する脂溶性物質の量を、以下のようにして測定した。
上記のようにして測定された、中空糸膜の全体に存在する脂溶性物質の含有量及び中空糸膜の表面に存在する脂溶性物質の含有量から、中空糸膜の全体に存在する脂溶性物質の含有量に対する中空糸膜の表面に存在する脂溶性物質の含有量の比率を算出した。なお、表1中、「膜表面VEの割合(%)」と表記した。
注射用水1Lにクエン酸三ナトリウム二水和物30g、ブドウ糖23.2g、クエン酸一水和物3.58g、リン酸二水素ナトリウム二水和物2.51gを溶解して抗凝固剤(CPD)を作成した。牛新鮮血5LにCPDを614mL添加して抗凝固化牛血液を得た。得られた血液を3500rpm、20分間遠心して血漿を分離した。得られた血漿は生理食塩水で希釈し総蛋白濃度を6.5±0.5g/dLに調整した。さらにβ2MG(栄研化学)を1Lあたり1mg添加し、血液側試験液とした。別途純水20Lに塩化ナトリウム121.54g、塩化カリウム2.98g、塩化マグネシウム8.14g、酢酸ナトリウム9.83g、ブドウ糖10gを溶解して透析側試験液を作成した。血液側試験液及び透析液側試験液のいずれも37±1℃に保温して試験に供した。
上記の抗凝固化牛血液を用い、牛血漿あるいは生理食塩水で希釈し、ヘマトクリットを35±2% 、総蛋白濃度6.5±0.5g/dLに調製した。該血液を血液浄化器の血液流路に200mL/minで循環させながら、市販透析液(扶桑薬品工業製、キンダリー透析液AF2号)を血液浄化器の血液流路に500mL/min、ワンパスで送液し、除水を6ml/min/m2で行いながら透析を実施した。なお、アルブミン漏出量全積算値(=アルブミン漏出量4時間積算値)、アルブミン漏出量1時間積算値に対するアルブミン漏出量5分間積算値の比率、及びアルブミン漏出量4時間積算値に対するアルブミン漏出量5分間積算値の比率の3項目の測定のため、1条件においてアルブミン漏出量を(1)5分積算時点、(2)1時間積算時点、(3)4時間積算時点の3回測定する。透析液の送液は、日機装社製DBG-03を用いた。溶血を防止する目的で血液浄化器は予め生理食塩水で十分に置換しておく。牛血液循環開始と同時に透析液送液、除水を開始し、除水液のサンプリングを開始した。除水液のみのサンプリングが難しい場合は、透析廃液すべてを集めてもよい。除水液、又は透析廃液を循環開始より(1)0~5分間、(2)5分~1時間、(3)1~4時間の間サンプリングを行い、それぞれ試験液(1)、試験液(2)、試験液(3)とした。各試験液をよく混和し、試験液中のアルブミン濃度(単位:g/mL)を、イアトロU-ALB(TIA)試薬(三菱化学メディエンス(株)製)を用いて、自動分析装置Biolis24i(東京貿易メディカルシステム株式会社)にて定量した。アルブミン漏出量全積算値(=アルブミン漏出量4時間積算値)、アルブミン漏出量1時間積算値に対するアルブミン漏出量5分間積算値の比率、及びアルブミン漏出量4時間積算値に対するアルブミン漏出量5分間積算値の比率は試験液(1)~(3)の濃度と除水液量(単位:mL)から以下の数式(11)、数式(12)、数式(13)、数式(14)、及び数式(15)により算出した。
中空糸膜型の血液浄化器内の、炭素数1~4のケトン及び/又はアルコール(以下、「成分A」という)の、中空糸膜1gあたりの含有量を、以下の方法により測定した。
血液浄化器を解体し、中空糸膜を取り出し、市販の遠心分離機を用いて3500rpmで10分間遠心分離して水分を除去した。水分を除去した中空糸膜のうち0.25gを秤取した(この質量を「w1(g)」とした)。25gのN-メチル-2-ピロリドンを加えて溶解した後、ガスクロマトグラフ(GC)により成分A、ジエチルエーテル、テトラヒドロフランの定量を行った。該当する成分Aのピーク面積から得た検量線を用いて、回収液中の成分A、ジエチルエーテル、テトラヒドロフランの濃度x(%)を求めた。
中空糸膜型血液浄化器の解体を行って、中空糸膜束を取り出した。塩化カルシウム乾燥剤としたデシケーター中で恒量となるまで乾燥を行い、この質量を精秤した(「w3(g)」)後、N-メチル-2-ピロリドン(「w4(g)」とする)を加え、攪拌し、溶解した後、上記方法で成分Aの濃度y(w/w%)を算出した。続いて、w3とyを以下の数式(16)に代入して中空糸膜1gあたりの成分Aの含有量を算出した。
ポリスルホン(ソルベイ社製P-1700)17.5重量%、ポリビニルピロリドン(BASF社製K90)3.5重量%を、N,N-ジメチルアセトアミド79.0重量%に溶解して均一な溶液とした。ここで、製膜原液中のポリスルホンに対するポリビニルピロリドンの混和比率は20.0重量%であった。この製膜原液を60℃に保ち、N,N-ジメチルアセトアミド58.1重量%と水41.9重量%との混合溶液からなる内部液とともに、2重環状紡口から吐出させ、0.96mのエアーギャップを通過させて75℃の水からなる凝固浴へ浸漬し、80m/分にて巻き取った。巻き取った糸束を切断後、束の切断面上方から80℃の熱水シャワーを2時間かけて洗浄することにより膜中の残溶剤を除去し、該膜をさらに乾燥することにより含水量が1%未満の乾燥膜を得た。さらに、該乾燥膜を、液体の導入及び導出用の2本のノズルを有する筒状容器に充填して両端部をウレタン樹脂で包埋後、硬化したウレタン部分を切断して中空糸膜が開口した端部に加工した。この両端部に血液導入(導出)用のノズルを有するヘッダーキャップを装填し、中空糸膜面積が1.5m2の血液浄化装置の形状に組み上げた。
内部液のN,N-ジメチルアセトアミドを57.1重量%、被覆溶液の脂溶性物質の濃度を0.15質量%とし、エタノール蒸気を乾燥空気に吹き込んだ以外は実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質の含有量を測定した結果、20.0mg/m2、中空糸膜の全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は70質量%、β2MGのクリアランスは70mL/min、中空糸膜1g中の成分A(ここでは、エタノールであった)の含有量は2000μgであった。
内部液のN,N-ジメチルアセトアミドを59.5重量%、被覆溶液の脂溶性物質の濃度を0.90質量%とし、アセトン蒸気を乾燥空気に吹き込んだ以外は実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質の含有量を測定した結果、200.0mg/m2、中空糸膜の全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は70質量%、β2MGのクリアランスは70mL/min、中空糸膜1g中の成分A(ここでは、アセトンであった)の含有量は2000μgであった。
内部液のN,N-ジメチルアセトアミドを55.0重量%、化学式(1)に示すポリスルホンの代わりに化学式(2)に示すポリエーテルスルホン(住友化学社製4800P)を用いた以外は、実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質の含有量を測定した結果、60.0mg/m2、中空糸膜の全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は70質量%、β2MGのクリアランスは70mL/min、中空糸膜1g中の成分A(ここでは、イソプロパノールであった)の含有量は2000μgであった。
内部液のN,N-ジメチルアセトアミドを55.5重量%とした以外は実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質含有量を測定した結果、60.0mg/m2、中空糸膜全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は70質量%、β2MGのクリアランスは65mL/min、中空糸膜1g中の成分A(ここでは、イソプロパノールであった)の含有量は2000μgであった。
脂溶性物質被覆溶液を中空糸膜の内腔部に40℃温度で通液及び乾燥した以外は、実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質の含有量を測定した結果、60.0mg/m2、中空糸膜の全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は45質量%、β2MGのクリアランスは70mL/min、中空糸膜1g中の成分A(ここでは、イソプロパノールであった)の含有量は10μgであった。
脂溶性物質被覆溶液を中空糸膜の内腔部に20℃温度で通液及び乾燥した以外は、実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質の含有量を測定した結果、60.0mg/m2、中空糸膜の全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は90質量%、β2MGのクリアランスは70mL/min、中空糸膜1g中の成分A(ここでは、イソプロパノールであった)の含有量は3000μgであった。
内部液のN,N-ジメチルアセトアミドを55.5重量%、脂溶性物質被覆工程及び成分Aの固定化工程を有しない以外は、実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質含有量を測定した結果、0mg/m2、中空糸膜全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は0質量%、β2MGのクリアランスは70mL/min、中空糸膜1g中の成分Aの含有量は0μgであった。
内部液のN,N-ジメチルアセトアミドを48.0重量%とした以外は実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質の含有量を測定した結果、60mg/m2、中空糸膜の全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は70質量%、β2MGのクリアランスは45mL/min、中空糸膜1g中の成分A(ここでは、イソプロパノールであった)の含有量は2000μgであった。
脂溶性物質被覆工程を行わない以外は、比較例2と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質の含有量を測定した結果、0mg/m2、中空糸膜の全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は0質量%、β2MGのクリアランスは45mL/min、中空糸膜1g中の成分Aの含有量は0μgであった。
ポリエーテルスルホン18.0重量%、ポリビニルピロリドン3.0重量%を、N,N-ジメチルアセトアミド74.5重量%、水4.5重量%に溶解して均一な溶液とし、内部液のN,N-ジメチルアセトアミドを46.0重量%とし、脂溶性物質被覆工程に用いる被覆溶液をα-トコフェロールを含まないイソプロパノール57重量%の水溶液にて行った以外は、実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質含有量を測定した結果、0mg/m2、中空糸膜の全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は0質量%、β2MGのクリアランスは60mL/min、中空糸膜1g中の成分A(ここでは、イソプロパノールであった)の含有量は2000μgであった。
脂溶性物質被覆溶液を中空糸膜の内腔部に55℃温度で通液及び乾燥した以外は、実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質の含有量を測定した結果、60.0mg/m2、中空糸膜の全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は30質量%、β2MGのクリアランスは70mL/min、中空糸膜1g中の成分A(ここでは、イソプロパノールであった)の含有量は2000μgであった。
内腔部に存在する被覆溶液の残液を除去した後、乾燥空気に成分Aの蒸気を吹き込まず、乾燥温度を80℃とした以外は実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器内の中空糸膜の脂溶性物質含有量を測定した結果、60.0mg/m2、中空糸膜の全体に存在する脂溶性物質に対する内表面に存在する脂溶性物質の割合は70質量%、β2MGのクリアランスは70mL/min、中空糸膜1g中の成分A(ここでは、イソプロパノールであった)の含有量は1μgであった。
内腔部に存在する被覆溶液の残液を除去した後、乾燥空気をジエチルエーテル雰囲気とした以外は実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器の中空糸膜の諸物性を測定しようと試みたが膜の液透過量が過少であり、測定できなかった。
内腔部に存在する被覆溶液の残液を除去した後、乾燥空気をテトラヒドロフラン雰囲気とした以外は実施例1と同様の方法により血液浄化器を得た。得られた血液浄化器の中空糸膜の諸物性を測定しようと試みたが膜の液透過量が過少であり、測定できなかった。
Claims (6)
- ポリスルホン系樹脂、親水性高分子及び脂溶性物質を含む、ポリスルホン系血液処理用中空糸膜において、
前記膜の表面に存在する前記脂溶性物質の量が1m2あたり10~300mgであり、
前記膜の全体に存在する前記脂溶性物質の含有量を100質量%とした場合、前記膜の表面に存在する前記脂溶性物質の含有量が40~95質量%であり、
前記膜を用いて組み立てられた血液浄化器の1.5m2換算したβ2MGのクリアランス値が65mL/min以上である
ことを特徴とする、ポリスルホン系血液処理用中空糸膜。 - 血液処理開始から1時間後までのアルブミン漏出の合計量を100質量%とした場合、血液処理開始から5分間後までのアルブミン漏出量が50%以下であることを特徴とする、請求項1に記載のポリスルホン系血液処理用中空糸膜。
- 血液処理の全期間にわたるアルブミン漏出の合計量が1.0g/session以上であることを特徴とする、請求項1又は2に記載のポリスルホン系血液処理用中空糸膜。
- 前記1.5m2換算したβ2MGのクリアランスが70mL/min以上であることを特徴とする、請求項1~3のいずれか一項に記載のポリスルホン系血液処理用中空糸膜。
- 前記脂溶性物質が脂溶性ビタミンであることを特徴とする、請求項1~4のいずれか一項に記載のポリスルホン系血液処理用中空糸膜。
- 炭素数が1~4のケトン及び/又はアルコールを中空糸膜1gあたり2~3000μg含むことを特徴とする、請求項1~5のいずれか一項に記載のポリスルホン系血液処理用中空糸膜。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015512331A JP6078641B2 (ja) | 2013-04-19 | 2014-02-14 | 血液処理用中空糸膜及び当該血液処理用中空糸膜の製造方法 |
EP14784797.4A EP2987514B1 (en) | 2013-04-19 | 2014-02-14 | Hollow fiber membrane for blood treatment |
CN201480021024.3A CN105142693B (zh) | 2013-04-19 | 2014-02-14 | 血液处理用中空纤维膜以及该血液处理用中空纤维膜的制造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013088352 | 2013-04-19 | ||
JP2013-088352 | 2013-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014171172A1 true WO2014171172A1 (ja) | 2014-10-23 |
Family
ID=51731133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/053488 WO2014171172A1 (ja) | 2013-04-19 | 2014-02-14 | 血液処理用中空糸膜及び当該血液処理用中空糸膜の製造方法 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2987514B1 (ja) |
JP (1) | JP6078641B2 (ja) |
CN (1) | CN105142693B (ja) |
WO (1) | WO2014171172A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016140616A (ja) * | 2015-02-03 | 2016-08-08 | 旭化成メディカル株式会社 | 中空糸膜型血液浄化器およびその製造方法 |
JP2020508869A (ja) * | 2017-02-01 | 2020-03-26 | フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 生体適合性が改善され、かつ親水性ポリマーの溶出が低減された中空繊維膜 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6383631B2 (ja) * | 2014-10-17 | 2018-08-29 | 旭化成メディカル株式会社 | 中空糸膜型血液浄化器 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0438583B2 (ja) | 1988-12-28 | 1992-06-24 | ||
JPH07178166A (ja) | 1993-12-24 | 1995-07-18 | Terumo Corp | 人工臓器 |
JPH0966225A (ja) * | 1995-06-22 | 1997-03-11 | Terumo Corp | 中空糸膜の製造方法ならびに中空糸膜およびダイアライザー |
JPH10235171A (ja) * | 1996-12-25 | 1998-09-08 | Terumo Corp | 中空糸膜の製造方法ならびに中空糸膜および中空糸膜型ダイアライザー |
JPH10244000A (ja) * | 1997-03-07 | 1998-09-14 | Terumo Corp | 中空糸膜型体液浄化装置およびその製造方法 |
WO1998052683A1 (fr) | 1997-05-19 | 1998-11-26 | Asahi Medical Co., Ltd. | Membrane hemocathartique en fibres creuses a base de polysulfone et ses procedes de production |
JPH11178919A (ja) * | 1997-12-17 | 1999-07-06 | Terumo Corp | 人工臓器の製造方法 |
JPH11347117A (ja) * | 1998-06-09 | 1999-12-21 | Terumo Corp | 中空糸膜および中空糸膜型人工腎臓 |
JP2005270631A (ja) | 2004-12-06 | 2005-10-06 | Toyobo Co Ltd | 選択透過性分離膜 |
JP2006296931A (ja) | 2005-04-25 | 2006-11-02 | Asahi Kasei Medical Co Ltd | 中空糸型血液浄化装置およびその製造方法 |
WO2008146775A1 (ja) * | 2007-05-25 | 2008-12-04 | Asahi Kasei Kuraray Medical Co., Ltd. | ポリスルホン系血液処理膜、およびその製造方法 |
WO2011090197A1 (ja) * | 2010-01-25 | 2011-07-28 | 旭化成クラレメディカル株式会社 | 中空糸膜型血液浄化装置 |
JP2011212638A (ja) | 2010-04-02 | 2011-10-27 | Toyobo Co Ltd | 中空糸膜 |
WO2012169529A1 (ja) * | 2011-06-09 | 2012-12-13 | 旭化成メディカル株式会社 | 血液処理用中空糸膜及び中空糸膜型血液処理装置 |
WO2013015046A1 (ja) * | 2011-07-27 | 2013-01-31 | 旭化成メディカル株式会社 | 中空糸膜型血液浄化装置 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2203657T3 (es) * | 1995-06-22 | 2004-04-16 | Asahi Medical Co., Ltd. | Metodo para la produccion de una membrana de fibras huecas, membrana de fibras huecas y dializador. |
EP0850678B1 (en) * | 1996-12-25 | 2006-05-24 | Asahikasei Medical Co., Ltd. | Process for producing hollow fiber membrane, hollow fiber membrane, and dialyzer of hollow fiber membrane type |
EP0923955B1 (en) * | 1997-12-17 | 2008-06-18 | Asahi Kasei Kuraray Medical Co., Ltd. | Manufacturing method of artificial organ, hollow fiber membrane, and dialyzer of hollow fiber membrane type |
CN1298397C (zh) * | 1998-11-09 | 2007-02-07 | 旭化成医疗株式会社 | 血液净化器 |
JP4144844B2 (ja) * | 2002-01-29 | 2008-09-03 | 旭化成クラレメディカル株式会社 | 中空糸膜型透析濾過器 |
KR20070058463A (ko) * | 2004-08-30 | 2007-06-08 | 도레이 가부시끼가이샤 | 분획 장치 |
JP2013009761A (ja) * | 2011-06-28 | 2013-01-17 | Asahi Kasei Medical Co Ltd | 中空糸膜型血液浄化装置及び中空糸膜型血液浄化装置の製造方法 |
JP6059040B2 (ja) * | 2013-02-27 | 2017-01-11 | 旭化成メディカル株式会社 | 血液処理用中空糸膜、当該血液処理用中空糸膜を具備する血液浄化器、及び当該血液浄化器の製造方法 |
-
2014
- 2014-02-14 JP JP2015512331A patent/JP6078641B2/ja active Active
- 2014-02-14 WO PCT/JP2014/053488 patent/WO2014171172A1/ja active Application Filing
- 2014-02-14 EP EP14784797.4A patent/EP2987514B1/en active Active
- 2014-02-14 CN CN201480021024.3A patent/CN105142693B/zh active Active
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0438583B2 (ja) | 1988-12-28 | 1992-06-24 | ||
JPH07178166A (ja) | 1993-12-24 | 1995-07-18 | Terumo Corp | 人工臓器 |
JPH0966225A (ja) * | 1995-06-22 | 1997-03-11 | Terumo Corp | 中空糸膜の製造方法ならびに中空糸膜およびダイアライザー |
JPH10235171A (ja) * | 1996-12-25 | 1998-09-08 | Terumo Corp | 中空糸膜の製造方法ならびに中空糸膜および中空糸膜型ダイアライザー |
JPH10244000A (ja) * | 1997-03-07 | 1998-09-14 | Terumo Corp | 中空糸膜型体液浄化装置およびその製造方法 |
WO1998052683A1 (fr) | 1997-05-19 | 1998-11-26 | Asahi Medical Co., Ltd. | Membrane hemocathartique en fibres creuses a base de polysulfone et ses procedes de production |
JPH11178919A (ja) * | 1997-12-17 | 1999-07-06 | Terumo Corp | 人工臓器の製造方法 |
JPH11347117A (ja) * | 1998-06-09 | 1999-12-21 | Terumo Corp | 中空糸膜および中空糸膜型人工腎臓 |
JP2005270631A (ja) | 2004-12-06 | 2005-10-06 | Toyobo Co Ltd | 選択透過性分離膜 |
JP2006296931A (ja) | 2005-04-25 | 2006-11-02 | Asahi Kasei Medical Co Ltd | 中空糸型血液浄化装置およびその製造方法 |
WO2008146775A1 (ja) * | 2007-05-25 | 2008-12-04 | Asahi Kasei Kuraray Medical Co., Ltd. | ポリスルホン系血液処理膜、およびその製造方法 |
WO2011090197A1 (ja) * | 2010-01-25 | 2011-07-28 | 旭化成クラレメディカル株式会社 | 中空糸膜型血液浄化装置 |
JP2011212638A (ja) | 2010-04-02 | 2011-10-27 | Toyobo Co Ltd | 中空糸膜 |
WO2012169529A1 (ja) * | 2011-06-09 | 2012-12-13 | 旭化成メディカル株式会社 | 血液処理用中空糸膜及び中空糸膜型血液処理装置 |
WO2013015046A1 (ja) * | 2011-07-27 | 2013-01-31 | 旭化成メディカル株式会社 | 中空糸膜型血液浄化装置 |
Non-Patent Citations (2)
Title |
---|
MICHIO MINESHIMA: "Ketsueki Johkaki -Seinohhyohkano Kiso (Blood Purifier - Basis for Performance Evaluation", 2002, NIPPON MEDICAL CENTER |
TAKESHI SATOH, JOURNAL OF THE JAPANESE SOCIETY FOR DIALYSIS THERAPY, vol. 29, no. 8, 1996, pages 1231 - 1245 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016140616A (ja) * | 2015-02-03 | 2016-08-08 | 旭化成メディカル株式会社 | 中空糸膜型血液浄化器およびその製造方法 |
JP2020508869A (ja) * | 2017-02-01 | 2020-03-26 | フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 生体適合性が改善され、かつ親水性ポリマーの溶出が低減された中空繊維膜 |
JP7200133B2 (ja) | 2017-02-01 | 2023-01-06 | フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 生体適合性が改善され、かつ親水性ポリマーの溶出が低減された中空繊維膜 |
Also Published As
Publication number | Publication date |
---|---|
CN105142693A (zh) | 2015-12-09 |
EP2987514A1 (en) | 2016-02-24 |
JP6078641B2 (ja) | 2017-02-08 |
JPWO2014171172A1 (ja) | 2017-02-16 |
CN105142693B (zh) | 2017-03-08 |
EP2987514A4 (en) | 2016-05-18 |
EP2987514B1 (en) | 2022-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4211168B2 (ja) | 透析器の製造方法および滅菌法 | |
EP3085400B1 (en) | Hollow fiber membrane blood purification device | |
AU2008303785B2 (en) | Hydrophilic membranes with a non-ionic surfactant | |
JP5758001B2 (ja) | 血液処理用中空糸膜及び中空糸膜型血液処理装置 | |
JP6375383B2 (ja) | 中空糸膜型血液浄化装置 | |
JP6059040B2 (ja) | 血液処理用中空糸膜、当該血液処理用中空糸膜を具備する血液浄化器、及び当該血液浄化器の製造方法 | |
WO2011090197A1 (ja) | 中空糸膜型血液浄化装置 | |
JP6078641B2 (ja) | 血液処理用中空糸膜及び当該血液処理用中空糸膜の製造方法 | |
JP6383631B2 (ja) | 中空糸膜型血液浄化器 | |
JP4923902B2 (ja) | 血液浄化用中空糸膜およびその製造方法 | |
JP6456034B2 (ja) | 血液処理用中空糸膜 | |
JP6190714B2 (ja) | 中空糸膜型血液浄化装置 | |
JP2013009761A (ja) | 中空糸膜型血液浄化装置及び中空糸膜型血液浄化装置の製造方法 | |
JP6502111B2 (ja) | 中空糸膜型血液浄化器およびその製造方法 | |
WO2023080238A1 (ja) | 中空糸膜型血液浄化器 | |
JP2007054470A (ja) | 血液浄化用中空糸膜およびその製造方法 | |
JP6817240B2 (ja) | 中空糸膜型血液浄化器 | |
WO2023080237A1 (ja) | 中空糸膜型血液浄化器 | |
JP2011041830A (ja) | 血液浄化用中空糸膜およびその製造方法 | |
JP2012005845A (ja) | 血液浄化用中空糸膜の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480021024.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14784797 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015512331 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014784797 Country of ref document: EP |